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ARTICLES
Clinical and biochemical
features of acute viral
hepatitis
C. W. Speannan
Viral hepatitis is a major cause of mortality and morbidity
worldwide. Acute viral hepatitis, although a generalised
systemic infection, presents with clinical manifestations
relating directly to inflammation of the liver with
hepatocellular dysfunction and jaundice.
MRC/UCT Liver Research Centre, Department of Medicine,
University of Cape Town
C. W. Spearman. M.B. CH.B.• M.MED.• F.C.P. (SA)
The most important causes of acute and chronic hepatitis
are the five hepatotrophic viruses, hepatitis A, B, C, D and E.
There are 2 other, as yet unidentified, hepatitis viruses, F
and G.
The clinical features of acute hepatitis caused by these
hepatotrophic viruses are similar and only minor features of
the clinical disease, together with the incubation period and
epidemiological history, help to distinguish the different acute
hepatitides. Specific diagnosis requires serological testing.
The clinical severity of acute hepatitis varies. Most
infections are asymptomatic, subclinical or anicteric with
mild gastro-intestinal symptoms only. Occasionally infection
results in acute fulminant hepatitis with an associated_ high
mortality.
Clinical features of acute viral
hepatitis
A full clinical history is important. Particular emphasis should
be paid to a recent history of travel, high-risk sexual
practices, blood transfusions and the use of drugs.
Symptoms
The most common symptoms experienced during the
prodromal phase include: malaise and fatigue, myalgia,
anorexia, nausea and vomiting, right upper quadrant
discomfort and fever.' Between 5% and 15% of patients
with hepatitis B may develop a serum-sickness-Iike
syndrome. Other extrahepatic manifestations, which may
occur in acute viral hepatitis, include urticaria and
angioneurotic oedema, arthritis, vasculitic and renal lesions,
myocarditis and cardiomyopathy, pancreatitis and CSF
abnormalities! The prodromal symptoms usually last a few
days to 2 weeks and are followed by the development of
jaundice. However, jaundice may occur in the absence of
any prodromal symptoms. Frequently, the systemic
symptoms improve with the development of jaundice.
Occasionally there is a prolonged cholestatic phase with
associated pruritus. If there are minimal prodromal
symptoms it is often difficult clinically to distinguish this form
of viral hepatitis from extrahepatic cholestasis or drug-
induced cholestasis.
During recovery, the nausea improves and the appetite
returns. General malaise may persist for some time and
relapses associated with an exacerbation of symptoms and
of jaundice occur in up to 5% of patients. These may be
precipitated by too early a· return to work or vigorous
exercise programmes.
Signs
The most common physical signs in acute hepatitis are
jaundice, right upper quadrant tenderness and mild
hepatomegaly. Splenomegaly occurs in 5 - 10% of patients
and lymphadenopathy is occasionally seen.' Skin rashes
may be present and in children with acute hepatitis B, a
papular acrodermatitis involving the arms, legs and face
may be found.
Fulminant viral hepatitis occurs in a small proportion of
patients. This is associated with the development of
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worsening jaundice and fulminant liver failure. Occasionally
the onset is so rapid that coma and death occur in the
absence of marked jaundice. The clinical signs are those of
fulminant liver failure: hepatic encephalopathy (deteriorating
level of consciousness, foetor hepaticus, asterixis and
constructional apraxia), gastro-intestinal bleeding due to
gastric erosions, coagulopathy, renal failure and
development of portal hypertension. Decreasing liver size
together with the development of ascites and oedema are
Door prognostic signs. It is important to stage the degree of
~ncephalopathyas, without transplantation, patients with
stage 4 coma have a less than 20% survival rate. Patients
with fulminant viral hepatitis and a deteriorating level of
consciousness should be managed at a centre experienced
in the multidisciplinary intensive care required; ideally, a liver
transplant programme should be available.
Biochemical features
The serum aspartate aminotransferase (AS1) and alanine
aminotransferase (AL1) activities are sensitive indices of
hepatocellular damage.' The rise in transaminase activity
begins in the prodromal phase, preceding the onset of
jaundice, and also occurs in those patients who remain
anicteric. There is usually an eight-fold or greater increase in
transaminase activities with the ALT being higher than the
AST. In uncomplicated cases the transaminase activities
decrease rapidly. Normal values are usually found by the
third week of the illness. The persistence of elevated
transaminase levels for longer than 6 months may imply
ongoing activity and progression of the disease. Although
transaminases are sensitive markers of hepatocellular
damage, they are not specific and cannot be used to predict
the outcome. There is no relationship between the degree of
transaminase activity and the severity of the disease. A
falling transaminase level together with clinical deterioration
and increasing coagulopathy may be found in extensive
hepatocyte necrosis and be associated with impending
fulminant liver failure.
Usually by the time the patient becomes overtly
jaundiced, the transaminase levels have peaked and are
beginning to fall. Senum bilirubin levels are variable and are
dependent on the degree of cholestasis. Most of the
bilirubin is conjugated. Fulminant hepatitis can occur in the
absence of significant hyperbilirubinaemia.
Urobilinogenuria may occur before the serum bilirubin
levels are elevated. Urobilinogen disappears from the urine
during the cholestatic phase and reappears during recovery.
Bilirubinuria may precede the onset of clinical jaundice and
persist during the cholestatic phase.
A small amount of circulating conjugated bilirubin usually
becomes covalently linked to albumin. This linkage is
irreversible and the bilirubin will persist in the circulation until
the albumin to which it is bound is degraded. This
hyperbilinubinaemia, which is not associated with
bilirubinuria, is of no clinical significance.
Serum alkaline phosphatase (ALP) levels are usually only
mildly elevated in acute viral hepatitis. However, where
cholestasis is marked, high levels of serum ALP activity may




Serum albumin concentrations are usually normal in mild
acute viral hepatitis. Low levels may be found in fulminant
hepatitis. Serum globulin levels frequently rise if the viral
hepatitis follows a prolonged course. Cryoglobulinaemia
may occasionally be seen. Serum u-fetoprotein
concentrations are usually raised during the acute illness'
and tend to rise as the serum transaminase levels fall,
suggesting that a-fetoprotein may be a marker of
regeneration.
There is some evidence that gluconeogenesis is reduced
in uncomplicated hepatitis. However, blood glucose levels
are usually maintained in these cases and the finding of
hypoglycaemia should suggest progression to fulminant
hepatitis.
Haematological changes
The haemoglobin concentration, white cell and platelet
counts and prothrombin international normalised ratio are
usually normal in uncomplicated viral hepatitis.
Early on in the illness, however, as in other viral infections,
a leukopenia, specifically a lymphocytopenia often with
atypical Iymphocytes, may occur. Later, relative
lymphocytosis, macrocytosis, reduced red cell survival' and
low serum haptoglobin levels may be seen. Occasionally,
thrombocytopenia, agranulocytosis, pancytopenia and
transient red cell aplasia may occur.6
The erythrocyte sedimentation rate is usually elevated
during the prodromal phase but decreases with the onset of
jaundice. Serum vitamin 8'2 levels are raised in acute viral
hepatitis as are serum iron levels. Fulminant viral hepatitis is
usually associated with a coagulopathy.
Frequency of investigations
While the initial biochemical tests allow the diagnosis of
hepatitis in general, serological tests are essential to
establish the aetiological diagnosis. The progress of any
patient with hepatitis is best monitored clinically and
repeated biochemical tests should only be used when
clinically indicated. Thus in uncomplicated cases of viral
hepatitis there may be no need to repeat the serum
biochemical tests. On the other hand, clinical deterioration
may suggest the need for further testing. In practice it
should seldom be necessary to repeat the biochemical tests
more than twice unless the disease is complicated by acute
liver failure or proceeds to chronic hepatitis.
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